Publications

  1. Rotenberg N, Feldman M, Shirian J, Hockla A, Radisky ES, Shifman JM. Engineered TIMP2 with narrow MMP-9 specificity is an effective inhibitor of invasion and proliferation of triple-negative breast cancer cells. J Biol Chem. 2024 Nov; 300 (11):107867 Epub 2024 Oct 15
    View PubMed
  2. Shirian J, Hockla A, Gleba JJ, Coban M, Rotenberg N, Strik LM, Alasonyalilar Demirer A, Pawlush ML, Copland JA, Radisky ES, Shifman JM. Improving Circulation Half-Life of Therapeutic Candidate N-TIMP2 by Unfolded Peptide Extension. Biomolecules. 2024 Sep 20; 14 (9) Epub 2024 Sept 20
    View PubMed
  3. Shirian J, Hockla A, Gleba JJ, Coban M, Rotenberg N, Strik LM, Alasonyalilar Demirer A, Pawlush ML, Copland JA, Radisky ES, Shifman JM. Improving Circulation Half-Life of Therapeutic Candidate N-TIMP2 by Unfolded Peptide Extension. bioRxiv. 2024 Jun 27 Epub 2024 June 27
    View PubMed
  4. Radisky ES. Extracellular proteolysis in cancer: Proteases, substrates, and mechanisms in tumor progression and metastasis. J Biol Chem. 2024 Jun; 300 (6):107347 Epub 2024 May 06
    View PubMed
  5. Ahmadighadykolaei H, Radisky ES, Raeeszadeh-Sarmazdeh M. Engineering Selective TIMPs Using a Counter-Selective Screening Strategy. Methods Mol Biol. 2024; 2747:257-278
    View PubMed
  6. Bonadio A, Wenig BL, Hockla A, Radisky ES, Shifman JM. Designed Loop Extension Followed by Combinatorial Screening Confers High Specificity to a Broad Matrix MetalloproteinaseInhibitor. J Mol Biol. 2023 Jul 1; 435 (13):168095 Epub 2023 Apr 15
    View PubMed
  7. Koistinen H, Kovanen RM, Hollenberg MD, Dufour A, Radisky ES, Stenman UH, Batra J, Clements J, Hooper JD, Diamandis E, Schilling O, Rannikko A, Mirtti T. The roles of proteases in prostate cancer. IUBMB Life. 2023 Jun; 75 (6):493-513 Epub 2023 Jan 04
    View PubMed
  8. Hayun H, Coban M, Bhagat AK, Ozer E, Alfonta L, Caulfield TR, Radisky ES, Papo N. Utilizing genetic code expansion to modify N-TIMP2 specificity towards MMP-2, MMP-9, and MMP-14. Sci Rep. 2023 Mar 30; 13 (1):5186
    View PubMed
  9. Shoari A, Khalili-Tanha G, Coban MA, Radisky ES. Structure and computation-guided yeast surface display for the evolution of TIMP-based matrix metalloproteinase inhibitors. Front Mol Biosci. 2023; 10:1321956 Epub 2023 Nov 23
    View PubMed
  10. Mehner C, Hockla A, Coban M, Madden B, Estrada R, Radisky DC, Radisky ES. Activity-based protein profiling reveals active serine proteases that drive malignancy of human ovarian clear cell carcinoma. J Biol Chem. 2022 Aug; 298 (8):102146 Epub 2022 June 16
    View PubMed
  11. Duch P, Diaz-Valdivia N, Ikemori R, Gabasa M, Radisky ES, Arshakyan M, Gea-Sorli S, Mateu-Bosch A, Bragado P, Carrasco JL, Mori H, Ramirez J, Teixido C, Reguart N, Fillat C, Radisky DC, Alcaraz J. Aberrant TIMP-1 overexpression in tumor-associated fibroblasts drives tumor progression through CD63 in lung adenocarcinoma. Matrix Biol. 2022 Aug; 111:207-225 Epub 2022 July 02
    View PubMed
  12. Raeeszadeh-Sarmazdeh M, Coban M, Mahajan S, Hockla A, Sankaran B, Downey GP, Radisky DC, Radisky ES. Engineering of tissue inhibitor of metalloproteinases TIMP-1 for fine discrimination between closely related stromelysins MMP-3 and MMP-10. J Biol Chem. 2022 Mar; 298 (3):101654 Epub 2022 Jan 29
    View PubMed
  13. Heyne M, Shirian J, Cohen I, Peleg Y, Radisky ES, Papo N, Shifman JM. Climbing Up and Down Binding Landscapes through Deep Mutational Scanning of Three Homologous Protein-Protein Complexes. J Am Chem Soc. 2021 Oct 20; 143 (41):17261-17275 Epub 2021 Oct 05
    View PubMed
  14. Gabasa M, Radisky ES, Ikemori R, Bertolini G, Arshakyan M, Hockla A, Duch P, Rondinone O, Llorente A, Maqueda M, Davalos A, Gavilan E, Perera A, Ramirez J, Gascon P, Reguart N, Roz L, Radisky DC, Alcaraz J. MMP1 drives tumor progression in large cell carcinoma of the lung through fibroblast senescence. Cancer Lett. 2021 Jun 1; 507:1-12 Epub 2021 Mar 06
    View PubMed
  15. Coban MA, Morrison J, Maharjan S, Hernandez Medina DH, Li W, Zhang YS, Freeman WD, Radisky ES, Le Roch KG, Weisend CM, Ebihara H, Caulfield TR. Attacking COVID-19 Progression Using Multi-Drug Therapy for Synergetic Target Engagement. Biomolecules. 2021 May 23; 11 (6)
    View PubMed
  16. Lacham-Hartman S, Shmidov Y, Radisky ES, Bitton R, Lukatsky DB, Papo N. Avidity observed between a bivalent inhibitor and an enzyme monomer with a single active site. PLoS One. 2021; 16 (11):e0249616 Epub 2021 Nov 30
    View PubMed
  17. Mehner C, Miller E, Hockla A, Coban M, Weroha SJ, Radisky DC, Radisky ES. Targeting an autocrine IL-6-SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma. Oncogene. 2020 Oct; 39(42):6606-6618. Epub 2020 Sep 14.
    View PubMed
  18. Aharon L, Aharoni SL, Radisky ES, Papo N. Quantitative mapping of binding specificity landscapes for homologous targets by using a high-throughput method. Biochem J. 2020 May 15; 477 (9):1701-1719
    View PubMed
  19. Kojima Y, Machida Y, Palani S, Caulfield TR, Radisky ES, Kaufmann SH, Machida YJ. FAM111A protects replication forks from protein obstacles via its trypsin-like domain. Nat Commun. 2020 Mar 12; 11 (1):1318
    View PubMed
  20. Gui F, Zhang Y, Wan J, Zhan X, Yao Y, Li Y, Haddock AN, Shi J, Guo J, Chen J, Zhu X, Edenfield BH, Zhuang L, Hu C, Wang Y, Mukhopadhyay D, Radisky ES, Zhang L, Lugea A, Pandol SJ, Bi Y, Ji B. Trypsin activity governs increased susceptibility to pancreatitis in mice expressing human PRSS1R122H. J Clin Invest. 2020 Jan 2; 130 (1):189-202
    View PubMed
  21. Radisky ES. Mirolysin structures open a window on gum disease. IUCrJ. 2020 Jan 1; 7 (Pt 1):3-4 Epub 2020 Jan 01
    View PubMed
  22. Raeeszadeh-Sarmazdeh M, Greene KA, Sankaran B, Downey GP, Radisky DC, Radisky ES. Directed evolution of the metalloproteinase inhibitor TIMP-1 reveals that its N- and C-terminal domains cooperate in matrix metalloproteinase recognition. J Biol Chem. 2019 Jun 14; 294 (24):9476-9488 Epub 2019 Apr 30
    View PubMed
  23. Cohen I, Coban M, Shahar A, Sankaran B, Hockla A, Lacham S, Caulfield TR, Radisky ES, Papo N. Disulfide engineering of human Kunitz-type serine protease inhibitors enhances proteolytic stability and target affinity toward mesotrypsin. J Biol Chem. 2019 Mar 29; 294(13):5105-5120. Epub 2019 Jan 30.
    View PubMed
  24. Ma H, Hockla A, Mehner C, Coban M, Papo N, Radisky DC, Radisky ES. PRSS3/Mesotrypsin and kallikrein-related peptidase 5 are associated with poor prognosis and contribute to tumor cell invasion and growth in lung adenocarcinoma. Sci Rep. 2019 Feb 12; 9(1):1844.
    View PubMed
  25. Mehner C, Radisky ES. Bad Tumors Made Worse: SPINK1. Front Cell Dev Biol. 2019; 7:10 Epub 2019 Feb 04
    View PubMed
  26. Jancso Z, Oracz G, Kujko AA, Kolodziejczyk E, Radisky ES, Rygiel AM, Sahin-Toth M. Novel Pathogenic PRSS1 Variant p.Glu190Lys in a Case of Chronic Pancreatitis. Front Genet. 2019; 10:46 Epub 2019 Feb 06
    View PubMed
  27. Naftaly S, Cohen I, Shahar A, Hockla A, Radisky ES, Papo N. Mapping protein selectivity landscapes using multi-target selective screening and next-generation sequencing of combinatorial libraries. Nat Commun. 2018 Sep 26; 9 (1):3935 Epub 2018 Sept 26
    View PubMed
  28. Sananes A, Cohen I, Shahar A, Hockla A, De Vita E, Miller AK, Radisky ES, Papo N. A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering. J Biol Chem. 2018 Aug 17; 293 (33):12663-12680 Epub 2018 June 22
    View PubMed
  29. Arkadash V, Radisky ES, Papo N. Combinatorial engineering of N-TIMP2 variants that selectively inhibit MMP9 and MMP14 function in the cell. Oncotarget. 2018 Aug 10; 9 (62):32036-32053
    View PubMed
  30. Cohen I, Naftaly S, Ben-Zeev E, Hockla A, Radisky ES, Papo N. Pre-equilibrium competitive library screening for tuning inhibitor association rate and specificity toward serine proteases. Biochem J. 2018 Apr 16; 475 (7):1335-1352
    View PubMed
  31. Shirian J, Arkadash V, Cohen I, Sapir T, Radisky ES, Papo N, Shifman JM. Converting a broad matrix metalloproteinase family inhibitor into a specific inhibitor of MMP-9 and MMP-14. FEBS Lett. 2018 Apr; 592 (7):1122-1134 Epub 2018 Mar 12
    View PubMed
  32. Radisky ES, Raeeszadeh-Sarmazdeh M, Radisky DC. Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer. J Cell Biochem. 2017 Nov; 118 (11):3531-3548 Epub 2017 July 17
    View PubMed
  33. Mehner C, Oberg AL, Goergen KM, Kalli KR, Maurer MJ, Nassar A, Goode EL, Keeney GL, Jatoi A, Radisky DC, Radisky ES. EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review. Genes Cancer. 2017 May; 8 (5-6):589-599
    View PubMed
  34. Arkadash V, Yosef G, Shirian J, Cohen I, Horev Y, Grossman M, Sagi I, Radisky ES, Shifman JM, Papo N. Development of High Affinity and High Specificity Inhibitors of Matrix Metalloproteinase 14 through Computational Design and Directed Evolution. J Biol Chem. 2017 Feb 24; 292 (8):3481-3495 Epub 2017 Jan 13
    View PubMed
  35. Kayode O, Huang Z, Soares AS, Caulfield TR, Dong Z, Bode AM, Radisky ES. Small molecule inhibitors of mesotrypsin from a structure-based docking screen. PLoS One. 2017; 12 (5):e0176694 Epub 2017 May 02
    View PubMed
  36. Kayode O, Wang R, Pendlebury DF, Cohen I, Henin RD, Hockla A, Soares AS, Papo N, Caulfield TR, Radisky ES. An Acrobatic Substrate Metamorphosis Reveals a Requirement for Substrate Conformational Dynamics in Trypsin Proteolysis. J Biol Chem. 2016 Dec 16; 291 (51):26304-26319 Epub 2016 Nov 03
    View PubMed
  37. Cichon MA, Moruzzi ME, Shqau TA, Miller E, Mehner C, Ethier SP, Copland JA, Radisky ES, Radisky DC. MYC Is a Crucial Mediator of TGFbeta-Induced Invasion in Basal Breast Cancer. Cancer Res. 2016 Jun 15; 76 (12):3520-30 Epub 2016 Apr 13
    View PubMed
  38. Cohen I, Kayode O, Hockla A, Sankaran B, Radisky DC, Radisky ES, Papo N. Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors as candidates for cancer therapy. Biochem J. 2016 May 15; 473 (10):1329-41 Epub 2016 Mar 08
    View PubMed
  39. Mehner C, Oberg AL, Kalli KR, Nassar A, Hockla A, Pendlebury D, Cichon MA, Goergen KM, Maurer MJ, Goode EL, Keeney GL, Jatoi A, Sahin-Toth M, Copland JA, Radisky DC, Radisky ES. Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers. Oncotarget. 2015 Nov 3; 6 (34):35737-54
    View PubMed
  40. Mehner C, Miller E, Nassar A, Bamlet WR, Radisky ES, Radisky DC. Tumor cell expression of MMP3 as a prognostic factor for poor survival in pancreatic, pulmonary, and mammary carcinoma. Genes Cancer. 2015 Nov; 6 (11-12):480-9
    View PubMed
  41. Alloy AP, Kayode O, Wang R, Hockla A, Soares AS, Radisky ES. Mesotrypsin Has Evolved Four Unique Residues to Cleave Trypsin Inhibitors as Substrates. J Biol Chem. 2015 Aug 28; 290 (35):21523-35 Epub 2015 July 14
    View PubMed
  42. Radisky ES, Radisky DC. Matrix metalloproteinases as breast cancer drivers and therapeutic targets. Front Biosci (Landmark Ed). 2015 Jun 1; 20 (7):1144-63 Epub 2015 June 01
    View PubMed
  43. Pendlebury D, Wang R, Henin RD, Hockla A, Soares AS, Madden BJ, Kazanov MD, Radisky ES. Sequence and conformational specificity in substrate recognition: several human Kunitz protease inhibitor domains are specific substrates of mesotrypsin. J Biol Chem. 2014 Nov 21; 289 (47):32783-97 Epub 2014 Oct 09
    View PubMed
  44. Mehner C, Miller E, Khauv D, Nassar A, Oberg AL, Bamlet WR, Zhang L, Waldmann J, Radisky ES, Crawford HC, Radisky DC. Tumor cell-derived MMP3 orchestrates Rac1b and tissue alterations that promote pancreatic adenocarcinoma. Mol Cancer Res. 2014 Oct; 12 (10):1430-9 Epub 2014 May 21
    View PubMed
  45. Mehner C, Hockla A, Miller E, Ran S, Radisky DC, Radisky ES. Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Oncotarget. 2014 May 15; 5 (9):2736-49
    View PubMed
  46. Szabo A, Radisky ES, Sahin-Toth M. Zymogen activation confers thermodynamic stability on a key peptide bond and protects human cationic trypsin from degradation. J Biol Chem. 2014; 289(8):4753-61.
    View PubMed
  47. Szabo A, Salameh MA, Ludwig M, Radisky ES, Sahin-Toth M. Tyrosine sulfation of human trypsin steers S2' subsite selectivity towards basic amino acids. PLoS One. 2014; 9 (7):e102063 Epub 2014 July 10
    View PubMed
  48. Chen F, Radisky ES, Das P, Batra J, Hata T, Hori T, Baine AM, Gardner L, Yue MY, Bu G, del Zoppo G, Patel TC, Nguyen JH. TIMP-1 attenuates blood-brain barrier permeability in mice with acute liver failure. J Cereb Blood Flow Metab. 2013 Jul; 33 (7):1041-9 Epub 2013 Mar 27
    View PubMed
  49. Batra J, Szabo A, Caulfield TR, Soares AS, Sahin-Toth M, Radisky ES. Long-range electrostatic complementarity governs substrate recognition by human chymotrypsin C, a key regulator of digestive enzyme activation. J Biol Chem. 2013 Apr 5; 288 (14):9848-9859 Epub 2013 Feb 19
    View PubMed
  50. Batra J, Soares AS, Mehner C, Radisky ES. Matrix metalloproteinase-10/TIMP-2 structure and analyses define conserved core interactions and diverse exosite interactions in MMP/TIMP complexes. PLoS One. 2013; 8 (9):e75836 Epub 2013 Sept 20
    View PubMed
  51. Salameh MA, Radisky ES. Biochemical and structural insights into mesotrypsin: an unusual human trypsin. Int J Biochem Mol Biol. 2013; 4(3):129-39. Epub 2013 Sep 13.
    View PubMed
  52. Hockla A, Miller E, Salameh MA, Copland JA, Radisky DC, Radisky ES. PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer. Mol Cancer Res. 2012 Dec; 10 (12):1555-66
    View PubMed
  53. Salameh MA, Soares AS, Alloy A, Radisky ES. Presence versus absence of hydrogen bond donor Tyr-39 influences interactions of cationic trypsin and mesotrypsin with protein protease inhibitors. Protein Sci. 2012 Aug; 21 (8):1103-12 Epub 2012 June 25
    View PubMed
  54. Stallings-Mann ML, Waldmann J, Zhang Y, Miller E, Gauthier ML, Visscher DW, Downey GP, Radisky ES, Fields AP, Radisky DC. Matrix metalloproteinase induction of Rac1b, a key effector of lung cancer progression. Sci Transl Med. 2012 Jul 11; 4 (142):142ra95
    View PubMed
  55. Liu H, Radisky DC, Yang D, Xu R, Radisky ES, Bissell MJ, Bishop JM. MYC suppresses cancer metastasis by direct transcriptional silencing of alphav and beta3 integrin subunits. Nat Cell Biol. 2012 Jun; 14(6):567-74. Epub 2012 May 13.
    View PubMed
  56. Batra J, Robinson J, Soares AS, Fields AP, Radisky DC, Radisky ES. Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure. J Biol Chem. 2012 May 4; 287 (19):15935-46 Epub 2012 Mar 16
    View PubMed
  57. Batra J, Robinson J, Mehner C, Hockla A, Miller E, Radisky DC, Radisky ES. PEGylation extends circulation half-life while preserving in vitro and in vivo activity of tissue inhibitor of metalloproteinases-1 (TIMP-1). PLoS One. 2012; 7 (11):e50028 Epub 2012 Nov 20
    View PubMed
  58. Justilien V, Regala RP, Tseng IC, Walsh MP, Batra J, Radisky ES, Murray NR, Fields AP. Matrix metalloproteinase-10 is required for lung cancer stem cell maintenance, tumor initiation and metastatic potential. PLoS One. 2012; 7 (4):e35040 Epub 2012 Apr 24
    View PubMed
  59. Salameh MA, Soares AS, Hockla A, Radisky DC, Radisky ES. The P(2)' residue is a key determinant of mesotrypsin specificity: engineering a high-affinity inhibitor with anticancer activity. Biochem J. 2011 Nov 15; 440 (1):95-105
    View PubMed
  60. Szabo A, Heja D, Szakacs D, Zboray K, Kekesi KA, Radisky ES, Sahin-Toth M, Pal G. High affinity small protein inhibitors of human chymotrypsin C (CTRC) selected by phage display reveal unusual preference for P4' acidic residues. J Biol Chem. 2011 Jun 24; 286(25):22535-45. Epub 2011 Apr 22.
    View PubMed
  61. Cichon MA, Radisky ES, Radisky DC. Identifying the stroma as a critical player in radiation-induced mammary tumor development. Cancer Cell. 2011 May 17; 19(5):571-2.
    View PubMed
  62. Salameh MA, Soares AS, Navaneetham D, Sinha D, Walsh PN, Radisky ES. Determinants of affinity and proteolytic stability in interactions of Kunitz family protease inhibitors with mesotrypsin. J Biol Chem. 2010 Nov 19; 285 (47):36884-96 Epub 2010 Sept 22
    View PubMed
  63. Hockla A, Radisky DC, Radisky ES. Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109. Breast Cancer Res Treat. 2010 Nov; 124 (1):27-38 Epub 2009 Dec 25
    View PubMed
  64. Orlichenko L, Geyer R, Yanagisawa M, Khauv D, Radisky ES, Anastasiadis PZ, Radisky DC. The 19-amino acid insertion in the tumor-associated splice isoform Rac1b confers specific binding to p120 catenin. J Biol Chem. 2010 Jun 18; 285 (25):19153-61 Epub 2010 Apr 15
    View PubMed
  65. Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia. 2010 Jun; 15 (2):201-12 Epub 2010 May 05
    View PubMed
  66. Salameh MA, Robinson JL, Navaneetham D, Sinha D, Madden BJ, Walsh PN, Radisky ES. The amyloid precursor protein/protease nexin 2 Kunitz inhibitor domain is a highly specific substrate of mesotrypsin. J Biol Chem. 2010 Jan 15; 285 (3):1939-49 Epub 2009 Nov 17
    View PubMed
  67. Chen CS, Nelson CM, Khauv D, Bennett S, Radisky ES, Hirai Y, Bissell MJ, Radisky DC. Homology with vesicle fusion mediator syntaxin-1a predicts determinants of epimorphin/syntaxin-2 function in mammary epithelial morphogenesis. J Biol Chem. 2009 Mar 13; 284(11):6877-84. Epub 2009 Jan 07.
    View PubMed
  68. Salameh MA, Soares AS, Hockla A, Radisky ES. Structural basis for accelerated cleavage of bovine pancreatic trypsin inhibitor (BPTI) by human mesotrypsin. J Biol Chem. 2008 Feb 15; 283 (7):4115-23 Epub 2007 Dec 12
    View PubMed
  69. Radisky ES, Radisky DC. Stromal induction of breast cancer: inflammation and invasion. Rev Endocr Metab Disord. 2007 Sep; 8 (3):279-87
    View PubMed
  70. Radisky ES, Lee JM, Lu CJ, Koshland DE Jr. Insights into the serine protease mechanism from atomic resolution structures of trypsin reaction intermediates. Proc Natl Acad Sci U S A. 2006 May 2; 103(18):6835-40. Epub 2006 Apr 24.
    View PubMed
  71. Radisky ES, Lu CJ, Kwan G, Koshland DE Jr. Role of the intramolecular hydrogen bond network in the inhibitory power of chymotrypsin inhibitor 2. Biochemistry. 2005 May 10; 44(18):6823-30.
    View PubMed
  72. Radisky ES, Kwan G, Karen Lu CJ, Koshland DE Jr. Binding, proteolytic, and crystallographic analyses of mutations at the protease-inhibitor interface of the subtilisin BPN'/chymotrypsin inhibitor 2 complex. Biochemistry. 2004 Nov 2; 43(43):13648-56.
    View PubMed
  73. Radisky ES, King DS, Kwan G, Koshland DE Jr. The role of the protein core in the inhibitory power of the classic serine protease inhibitor, chymotrypsin inhibitor 2. Biochemistry. 2003 Jun 3; 42(21):6484-92.
    View PubMed
  74. Radisky ES, Koshland DE Jr. A clogged gutter mechanism for protease inhibitors. Proc Natl Acad Sci U S A. 2002 Aug 6; 99(16):10316-21. Epub 2002 Jul 25.
    View PubMed
  75. Radisky ES, Poulter CD. Squalene synthase: steady-state, pre-steady-state, and isotope-trapping studies. Biochemistry. 2000 Feb 22; 39(7):1748-60.
    View PubMed
  76. Wu Z, Demma M, Strickland CL, Radisky ES, Poulter CD, Le HV, Windsor WT. Farnesyl protein transferase: identification of K164 alpha and Y300 beta as catalytic residues by mutagenesis and kinetic studies. Biochemistry. 1999 Aug 31; 38(35):11239-49.
    View PubMed
  77. Ajioka RS, Jorde LB, Gruen JR, Yu P, Dimitrova D, Barrow J, Radisky E, Edwards CQ, Griffen LM, Kushner JP. Haplotype analysis of hemochromatosis: evaluation of different linkage-disequilibrium approaches and evolution of disease chromosomes. Am J Hum Genet. 1997 Jun; 60(6):1439-47.
    View PubMed
  78. Radisky ES, Ajioka RS, Edwards CQ, Griffen LM, Kushner JP. Mapping recombinant events with molecular markers in hemochromatosis pedigrees. Cytogenet Cell Genet. 1994; 67(2):126-8.
    View PubMed
  79. Radisky DC, Radisky ES, Barrows LR, Copp BR, Kramer RA, Ireland CM. Novel cytotoxic topoisomerase II inhibiting pyrroloiminoquinones from Fijian sponges of the genus Zyzzya. J Am Chem Soc. 1993; 115:1632-8.
  80. Yu Y, Radisky E, Leibold EA. The iron-responsive element binding protein. Purification cloning, and regulation in rat liver. J Biol Chem. 1992 Sep 15; 267(26):19005-10.
    View PubMed
  81. Garey JR, Harrison LM, Franklin KF, Metcalf KM, Radisky ES, Kushner JP. Uroporphyrinogen decarboxylase: a splice site mutation causes the deletion of exon 6 in multiple families with porphyria cutanea tarda. J Clin Invest. 1990 Nov; 86(5):1416-22.
    View PubMed